Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Consensus Rating of “Moderate Buy” from Brokerages

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has earned an average recommendation of “Moderate Buy” from the nine ratings firms that are covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $42.13.

ARWR has been the topic of a number of analyst reports. Citigroup cut their price objective on shares of Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a “neutral” rating on the stock in a research report on Tuesday, May 13th. Chardan Capital reaffirmed a “buy” rating and set a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, May 13th. Wall Street Zen raised shares of Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday. HC Wainwright reissued a “buy” rating and issued a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Tuesday. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $42.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th.

Arrowhead Pharmaceuticals Trading Up 0.5%

ARWR opened at $15.39 on Friday. The stock has a 50-day moving average of $13.32 and a 200 day moving average of $17.70. The company has a current ratio of 6.09, a quick ratio of 6.09 and a debt-to-equity ratio of 7.27. Arrowhead Pharmaceuticals has a 12 month low of $9.57 and a 12 month high of $30.41. The firm has a market cap of $2.13 billion, a P/E ratio of -2.98 and a beta of 0.89.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its earnings results on Monday, May 12th. The biotechnology company reported $2.75 EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $2.81. The company had revenue of $542.71 million during the quarter, compared to analysts’ expectations of $116.27 million. During the same quarter last year, the firm posted ($1.02) EPS. As a group, research analysts forecast that Arrowhead Pharmaceuticals will post -2.42 EPS for the current year.

Insider Buying and Selling

In related news, CEO Christopher Richard Anzalone sold 50,800 shares of the business’s stock in a transaction that occurred on Friday, April 11th. The stock was sold at an average price of $11.49, for a total value of $583,692.00. Following the completion of the sale, the chief executive officer now owns 3,921,255 shares in the company, valued at approximately $45,055,219.95. The trade was a 1.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold 275,880 shares of company stock valued at $4,034,037 in the last 90 days. Company insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. GAMMA Investing LLC grew its position in shares of Arrowhead Pharmaceuticals by 297.6% during the 1st quarter. GAMMA Investing LLC now owns 2,175 shares of the biotechnology company’s stock worth $28,000 after buying an additional 1,628 shares in the last quarter. R Squared Ltd purchased a new stake in Arrowhead Pharmaceuticals in the fourth quarter worth about $38,000. GF Fund Management CO. LTD. bought a new position in Arrowhead Pharmaceuticals during the 4th quarter worth about $49,000. Van ECK Associates Corp grew its holdings in Arrowhead Pharmaceuticals by 72.3% during the 4th quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company’s stock worth $56,000 after acquiring an additional 1,250 shares in the last quarter. Finally, CWM LLC increased its position in Arrowhead Pharmaceuticals by 134.3% during the 1st quarter. CWM LLC now owns 4,401 shares of the biotechnology company’s stock valued at $56,000 after purchasing an additional 2,523 shares during the period. 62.61% of the stock is owned by institutional investors.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.